Drugs / LB101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05821777 | Mar 2023 → Jan 2025 | neoplasm | Centessa Pharmaceuticals (UK) Limited | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05821777 ↗ |
| Route | Intravenous | “IV infusion of LB101” NCT05821777 ↗ |